カテゴリー： QYResearch, 世界

世界の多発性硬化症（MS）治療薬市場 2019年

【英語タイトル】Global Multiple Sclerosis (MS) Drugs Market Professional Survey Report 2019

QYResearchが出版した調査資料（DATA909X11757）・商品コード：DATA909X11757
・発行会社（調査会社）：QYResearch
・発行日：2019年11月20日（※2024年版があります。お問い合わせください）
・ページ数：111
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥518,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,250 ⇒換算￥777,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,000 ⇒換算￥1,036,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※本調査レポートは、多発性硬化症（MS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他に、用途別には、RRMS、SPMS、PPMS、PRMSにセグメント区分し、多発性硬化症（MS）治療薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・多発性硬化症（MS）治療薬の世界市場概要
・多発性硬化症（MS）治療薬の製造コスト構成分析
・多発性硬化症（MS）治療薬の開発・製造工場分析
・主要メーカーの主な指標（生産能力、売上、価格分析）
・多発性硬化症（MS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・多発性硬化症（MS）治療薬のセグメント分析（種類別）
（コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他）
・多発性硬化症（MS）治療薬のセグメント分析（用途別）
（RRMS、SPMS、PPMS、PRMS）
・多発性硬化症（MS）治療薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績）
（Bayer AG、Bayhill Therapeutics、Biogen Idec、Cinnagen、Daiichi Sankyo、Eli Lilly、Fast Forward Llc、Antisense Therapeutics、Apitope、Five Prime Therapeutics、Genmab、Artielle Immunotherapeutics、Genzyme、Glaxosmithkline、Gw Pharmaceuticals、Innate Immunotherapeutics、）
・多発性硬化症（MS）治療薬の市場規模予測（2019年～2025年）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子）
...
【レポートの概要】

The global Multiple Sclerosis (MS) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Multiple Sclerosis (MS) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Multiple Sclerosis (MS) Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Multiple Sclerosis (MS) Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Multiple Sclerosis (MS) Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others

Segment by Application
RRMS
SPMS
PPMS
PRMS

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Multiple Sclerosis (MS) Drugs
1.1 Definition of Multiple Sclerosis (MS) Drugs
1.2 Multiple Sclerosis (MS) Drugs Segment by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Multiple Sclerosis (MS) Drugs Segment by Applications
1.3.1 Global Multiple Sclerosis (MS) Drugs Consumption Comparison by Applications (2014-2025)
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Global Multiple Sclerosis (MS) Drugs Overall Market
1.4.1 Global Multiple Sclerosis (MS) Drugs Revenue (2014-2025)
1.4.2 Global Multiple Sclerosis (MS) Drugs Production (2014-2025)
1.4.3 North America Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.4 Europe Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.5 China Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.6 Japan Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.7 Southeast Asia Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.8 India Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
2.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
2.4 Industry Chain Structure of Multiple Sclerosis (MS) Drugs

3 Development and Manufacturing Plants Analysis of Multiple Sclerosis (MS) Drugs
3.1 Capacity and Commercial Production Date
3.2 Global Multiple Sclerosis (MS) Drugs Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Multiple Sclerosis (MS) Drugs
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Multiple Sclerosis (MS) Drugs Production and Capacity Analysis
4.2 Multiple Sclerosis (MS) Drugs Revenue Analysis
4.3 Multiple Sclerosis (MS) Drugs Price Analysis
4.4 Market Concentration Degree

5 Multiple Sclerosis (MS) Drugs Regional Market Analysis
5.1 Multiple Sclerosis (MS) Drugs Production by Regions
5.1.1 Global Multiple Sclerosis (MS) Drugs Production by Regions
5.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Regions
5.2 Multiple Sclerosis (MS) Drugs Consumption by Regions
5.3 North America Multiple Sclerosis (MS) Drugs Market Analysis
5.3.1 North America Multiple Sclerosis (MS) Drugs Production
5.3.2 North America Multiple Sclerosis (MS) Drugs Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Multiple Sclerosis (MS) Drugs Import and Export
5.4 Europe Multiple Sclerosis (MS) Drugs Market Analysis
5.4.1 Europe Multiple Sclerosis (MS) Drugs Production
5.4.2 Europe Multiple Sclerosis (MS) Drugs Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Multiple Sclerosis (MS) Drugs Import and Export
5.5 China Multiple Sclerosis (MS) Drugs Market Analysis
5.5.1 China Multiple Sclerosis (MS) Drugs Production
5.5.2 China Multiple Sclerosis (MS) Drugs Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Multiple Sclerosis (MS) Drugs Import and Export
5.6 Japan Multiple Sclerosis (MS) Drugs Market Analysis
5.6.1 Japan Multiple Sclerosis (MS) Drugs Production
5.6.2 Japan Multiple Sclerosis (MS) Drugs Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Multiple Sclerosis (MS) Drugs Import and Export
5.7 Southeast Asia Multiple Sclerosis (MS) Drugs Market Analysis
5.7.1 Southeast Asia Multiple Sclerosis (MS) Drugs Production
5.7.2 Southeast Asia Multiple Sclerosis (MS) Drugs Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Multiple Sclerosis (MS) Drugs Import and Export
5.8 India Multiple Sclerosis (MS) Drugs Market Analysis
5.8.1 India Multiple Sclerosis (MS) Drugs Production
5.8.2 India Multiple Sclerosis (MS) Drugs Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Multiple Sclerosis (MS) Drugs Import and Export

6 Multiple Sclerosis (MS) Drugs Segment Market Analysis (by Type)
6.1 Global Multiple Sclerosis (MS) Drugs Production by Type
6.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type
6.3 Multiple Sclerosis (MS) Drugs Price by Type

7 Multiple Sclerosis (MS) Drugs Segment Market Analysis (by Application)
7.1 Global Multiple Sclerosis (MS) Drugs Consumption by Application
7.2 Global Multiple Sclerosis (MS) Drugs Consumption Market Share by Application (2014-2019)

8 Multiple Sclerosis (MS) Drugs Major Manufacturers Analysis
8.1 Bayer AG
8.1.1 Bayer AG Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.1.2 Bayer AG Product Introduction, Application and Specification
8.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Bayhill Therapeutics
8.2.1 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.2.2 Bayhill Therapeutics Product Introduction, Application and Specification
8.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Biogen Idec
8.3.1 Biogen Idec Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.3.2 Biogen Idec Product Introduction, Application and Specification
8.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Cinnagen
8.4.1 Cinnagen Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.4.2 Cinnagen Product Introduction, Application and Specification
8.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Daiichi Sankyo
8.5.1 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.5.2 Daiichi Sankyo Product Introduction, Application and Specification
8.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Eli Lilly
8.6.1 Eli Lilly Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.6.2 Eli Lilly Product Introduction, Application and Specification
8.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Fast Forward Llc
8.7.1 Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.7.2 Fast Forward Llc Product Introduction, Application and Specification
8.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Antisense Therapeutics
8.8.1 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.8.2 Antisense Therapeutics Product Introduction, Application and Specification
8.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served
8.9 Apitope
8.9.1 Apitope Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.9.2 Apitope Product Introduction, Application and Specification
8.9.3 Apitope Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.9.4 Main Business and Markets Served
8.10 Five Prime Therapeutics
8.10.1 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.10.2 Five Prime Therapeutics Product Introduction, Application and Specification
8.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.10.4 Main Business and Markets Served
8.11 Genmab
8.12 Artielle Immunotherapeutics
8.13 Genzyme
8.14 Glaxosmithkline
8.15 Gw Pharmaceuticals
8.16 Innate Immunotherapeutics

9 Development Trend of Analysis of Multiple Sclerosis (MS) Drugs Market
9.1 Global Multiple Sclerosis (MS) Drugs Market Trend Analysis
9.1.1 Global Multiple Sclerosis (MS) Drugs Market Size (Volume and Value) Forecast 2019-2025
9.2 Multiple Sclerosis (MS) Drugs Regional Market Trend
9.2.1 North America Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.2 Europe Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.3 China Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.4 Japan Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.5 Southeast Asia Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.6 India Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.3 Multiple Sclerosis (MS) Drugs Market Trend (Product Type)
9.4 Multiple Sclerosis (MS) Drugs Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Multiple Sclerosis (MS) Drugs Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Multiple Sclerosis (MS) Drugs
Table Global Multiple Sclerosis (MS) Drugs Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Multiple Sclerosis (MS) Drugs Production Market Share by Types in 2018
Figure Copaxone (Glatiramer Acetate, Copolymer 1) Product Picture
Figure Novantrone (Mitoxantrone) Product Picture
Figure Gilenya (Fingolimod, Fty720) Product Picture
Figure Aubagio (Teriflunomide) Product Picture
Figure Tecfidera (Dimethyl Fumarate) Product Picture
Figure Firategrast (Sb683699, T-0047) Product Picture
Figure Siponimod (Baf312) Product Picture
Figure Others Product Picture
Table Global Multiple Sclerosis (MS) Drugs Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Multiple Sclerosis (MS) Drugs Consumption Market Share by Applications in 2018
Figure RRMS
Figure SPMS
Figure PPMS
Figure PRMS
Figure Global Multiple Sclerosis (MS) Drugs Revenue (Million USD) (2014-2025)
Figure Global Multiple Sclerosis (MS) Drugs Production (K Pcs) (2014-2025)
Figure North America Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure Europe Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure China Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure Japan Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure India Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Table Multiple Sclerosis (MS) Drugs Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs in 2018
Figure Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure Industry Chain Structure of Multiple Sclerosis (MS) Drugs
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Multiple Sclerosis (MS) Drugs Manufacturing Plants Distribution
Table Multiple Sclerosis (MS) Drugs Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Multiple Sclerosis (MS) Drugs Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Multiple Sclerosis (MS) Drugs Production (K Pcs) of Major Manufacturers (2014-2019)
Table Multiple Sclerosis (MS) Drugs Production Market Share of Major Manufacturers (2014-2019)
Figure Multiple Sclerosis (MS) Drugs Production Share by Manufacturers in 2018
Table Multiple Sclerosis (MS) Drugs Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Multiple Sclerosis (MS) Drugs Revenue Market Share of Major Manufacturers (2014-2019)
Figure Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers in 2018
Table Multiple Sclerosis (MS) Drugs Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Multiple Sclerosis (MS) Drugs Production by Regions 2014-2019 (K Pcs)
Table Global Multiple Sclerosis (MS) Drugs Production Market Share by Regions 2014-2019
Figure Global Multiple Sclerosis (MS) Drugs Production Market Share by Regions in 2018
Table Global Multiple Sclerosis (MS) Drugs Revenue by Regions 2014-2019 (Million USD)
Table Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions 2014-2019
Figure Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions in 2018
Table Global Multiple Sclerosis (MS) Drugs Consumption by Regions 2014-2019 (K Pcs)
Table Global Multiple Sclerosis (MS) Drugs Consumption Market Share by Regions 2014-2019
Figure North America Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure North America Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table North America Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Europe Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure China Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure China Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table China Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Japan Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure India Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure India Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table India Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Multiple Sclerosis (MS) Drugs Market Share by Application (2014-2019)
Figure Global Value (Consumption) Multiple Sclerosis (MS) Drugs Market Share by Application (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Bayer AG Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Bayer AG Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Biogen Idec Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Biogen Idec Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Cinnagen Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Cinnagen Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Cinnagen Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Cinnagen Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Cinnagen Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Cinnagen Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Eli Lilly Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Eli Lilly Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Apitope Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Apitope Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Apitope Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Apitope Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Apitope Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Apitope Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Apitope Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Genmab Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Genzyme Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Glaxosmithkline Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Figure Global Multiple Sclerosis (MS) Drugs Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Multiple Sclerosis (MS) Drugs by Type (2019-2025)
Table Global Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs by Application (2019-2025)
Table Multiple Sclerosis (MS) Drugs Distributors List
Table Multiple Sclerosis (MS) Drugs Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Bayer AG、Bayhill Therapeutics、Biogen Idec、Cinnagen、Daiichi Sankyo、Eli Lilly、Fast Forward Llc、Antisense Therapeutics、Apitope、Five Prime Therapeutics、Genmab、Artielle Immunotherapeutics、Genzyme、Glaxosmithkline、Gw Pharmaceuticals、Innate Immunotherapeutics、

★調査レポート[世界の多発性硬化症（MS）治療薬市場 2019年] (コード：DATA909X11757)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の多発性硬化症（MS）治療薬市場 2019年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の多嚢胞性卵巣症候群（PCOS）治療薬市場 2019年
    DATA909X13285 / QYResearch / 2019年11月20日 / ※本調査レポートは、多嚢胞性卵巣症候群（PCOS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、経口避妊薬、抗炎症薬、インスリン抵抗性改善薬、抗高血圧薬、抗肥満薬に、用途別には、病院、クリニックにセグメント区分し、多嚢胞性卵巣症候群（PCOS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・多嚢胞性卵巣症候群（PCOS）治療薬の世界市場概要 ・多嚢胞性卵巣症候群（PCOS）治療薬の製造コスト構成分析 ・多嚢胞性卵巣症候群（PCOS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・多嚢胞性卵巣症候群（PCOS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・多嚢胞性卵巣症候群（PCOS）治療薬のセグメント分析（種類別） （経口避妊薬、抗炎症薬、インスリン抵抗性改善薬、抗高血圧薬、抗肥満薬）...The global Polycystic Ovary Syndrome (PCOS) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Polycystic Ovary Syndrome (PCOS) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Polycystic Ovary Syndrome (PCOS) Drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Polycystic Ovary Syndrome (PCOS) Drugs in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の骨髄異形成症候群（MDS）治療薬市場 2019年
    DATA909X11785 / QYResearch / 2019年11月20日 / ※本調査レポートは、骨髄異形成症候群（MDS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他に、用途別には、入院患者、外来患者にセグメント区分し、骨髄異形成症候群（MDS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・骨髄異形成症候群（MDS）治療薬の世界市場概要 ・骨髄異形成症候群（MDS）治療薬の製造コスト構成分析 ・骨髄異形成症候群（MDS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・骨髄異形成症候群（MDS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・骨髄異形成症候群（MDS）治療薬のセグメント分析（種類別） （アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他）...The global Myelodysplastic Syndrome (MDS) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Myelodysplastic Syndrome (MDS) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myelodysplastic Syndrome (MDS) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Myelodysplastic Syndrome (MDS) Therapeutics in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer...
  • 世界の呼吸器合胞体ウイルス（RSV）治療薬市場 2019年
    DATA909X14332 / QYResearch / 2019年11月20日 / ※本調査レポートは、呼吸器合胞体ウイルス（RSV）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、パリビズマブ、リバビリン、その他に、用途別には、病院薬局、ドラッグストア、小売薬局、その他にセグメント区分し、呼吸器合胞体ウイルス（RSV）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・呼吸器合胞体ウイルス（RSV）治療薬の世界市場概要 ・呼吸器合胞体ウイルス（RSV）治療薬の製造コスト構成分析 ・呼吸器合胞体ウイルス（RSV）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・呼吸器合胞体ウイルス（RSV）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・呼吸器合胞体ウイルス（RSV）治療薬のセグメント分析（種類別） （パリビズマブ、リバビリン、その他）...The global Respiratory Syncytial Virus (RSV) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Respiratory Syncytial Virus (RSV) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Respiratory Syncytial Virus (RSV) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Respiratory Syncytial Virus (RSV) Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の急性心不全(AHF)治療薬市場 2019年
    DATA909X02947 / QYResearch / 2019年11月15日 / ※本調査レポートは、急性心不全(AHF)治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、β遮断薬、カルシウム拮抗薬、強心配糖体、利尿薬、モルヒネ、血管拡張薬/硝酸塩、その他に、用途別には、病院、クリニック、ホームケアにセグメント区分し、急性心不全(AHF)治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・急性心不全(AHF)治療薬の世界市場概要 ・急性心不全(AHF)治療薬の製造コスト構成分析 ・急性心不全(AHF)治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・急性心不全(AHF)治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・急性心不全(AHF)治療薬のセグメント分析（種類別） （β遮断薬、カルシウム拮抗薬、強心配糖体、利尿薬、モルヒネ、血管拡張薬/硝酸塩、その他）...The global Acute Heart Failure (AHF) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Acute Heart Failure (AHF) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Heart Failure (AHF) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Acute Heart Failure (AHF) Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の急性呼吸窮迫症候群(ARDS)治療薬市場 2019年
    DATA909X02949 / QYResearch / 2019年11月15日 / ※本調査レポートは、急性呼吸窮迫症候群(ARDS)治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他に、用途別には、入院患者、外来患者にセグメント区分し、急性呼吸窮迫症候群(ARDS)治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・急性呼吸窮迫症候群(ARDS)治療薬の世界市場概要 ・急性呼吸窮迫症候群(ARDS)治療薬の製造コスト構成分析 ・急性呼吸窮迫症候群(ARDS)治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・急性呼吸窮迫症候群(ARDS)治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・急性呼吸窮迫症候群(ARDS)治療薬のセグメント分析（種類別） （メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他）...The global Acute Respiratory Distress Syndrome Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Acute Respiratory Distress Syndrome Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Respiratory Distress Syndrome Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Acute Respiratory Distress Syndrome Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の肺動脈高血圧症（PAH）治療薬市場 2019年
    DATA909X13888 / QYResearch / 2019年11月20日 / ※本調査レポートは、肺動脈高血圧症（PAH）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリンアナログ、ホスホジエステラーゼ5（PDE-5）、可溶性グアニル酸シクラーゼ（SGC）刺激剤に、用途別には、二次性肺高血圧症（SPH）、原発性肺高血圧症（PPH）にセグメント区分し、肺動脈高血圧症（PAH）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・肺動脈高血圧症（PAH）治療薬の世界市場概要 ・肺動脈高血圧症（PAH）治療薬の製造コスト構成分析 ・肺動脈高血圧症（PAH）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・肺動脈高血圧症（PAH）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・肺動脈高血圧症（PAH）治療薬のセグメント分析（種類別） （エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリンアナログ、ホスホジエステラーゼ5（PDE-5）、可溶性グアニル酸シクラーゼ（SGC）刺激剤）...The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Pulmonary Arterial Hypertension (PAH) Medicine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pulmonary Arterial Hypertension (PAH) Medicine market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Pulmonary Arterial Hypertension (PAH) Medicine in North America, Europe, China, Japan, Southeast Asia and...

    • ◆H&Iグローバルリサーチのお客様（例）◆